VivoSeq
Psychiatry

Anorexia Nervosa

44

Pipeline Programs

11

Active Trials

30

Companies Involved

Anorexia Nervosa is a moderately active landscape with 44 programs across 30 companies. The most active players are Homeostasis Therapeutics, LLC, Boehringer Ingelheim, Novo Nordisk. 6 therapies are approved with 9 more in late-stage development.

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

15/100

Mech. Concentration

8/100

Completion Rate

82/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

96%

Small molecule

47 of 49 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Peptide12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 54 pipeline programs.

Trial Status

60

clinical trials

Completed37 · 62%
Recruiting6 · 10%
Not yet recruiting4 · 7%
Withdrawn4 · 7%
Unknown status4 · 7%
Terminated4 · 7%
Other1 · 2%

Trial Activity

60 trials

Transdermal Estrogen in Women With Anorexia Nervosa
Recruiting··Phase 2·NCT03875378·66 enrolled
Metreleptin in Anorexia Nervosa
Recruiting··Phase 2·NCT06305182·50 enrolled
Fecal Microbiota Transplant for Anorexia Nervosa
Not yet recruiting·MMcMaster University·N/A·NCT06593366·20 enrolled
Constructing the Subjective Value of Food in Anorexia Nervosa
Not yet recruiting·UUniversity of Chicago·Preclinical·NCT07692945·150 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)